Dapagliflozin (DPG; Figure 1) is a medication prescribed for type 2 diabetes mellitus patients that acts as an inhibitor of the sodium-glucose cotransporter 2 (SGLT2) in the kidney. This evidence concerns the gene SLC5A2 and diabetes mellitus.